Drug
Sotorasib clinical trials
Also written AMG 510 and Lumakras.
- studies test it
- 50
- open now
- 16
- in phase 3
- 4
- first study started
- 2019
Keep track of what changes. Save the sotorasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2022 (15)
| Year | Studies |
|---|---|
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 15 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 29
- Phase 2
- 21
- Phase 3
- 4
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 22
Amgen (21) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (2) · NYU Langone Health (2) · Verastem, Inc. (1) · SWOG Cancer Research Network (1) · Korea University Anam Hospital (1) · Revolution Medicines, Inc. (1)
Often tested with
Tested in the same studies.
Panitumumab (6) · Trastuzumab deruxtecan (3) · Omeprazole (2) · Fulvestrant (2) · Bevacizumab (2) · Ladarixin (2) · RO5126766 (1) · Defactinib (1)
Studies
Open first, then newest update. How each study uses sotorasib is read from its arms, and is right about nine times in ten.
Testing it · 50
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingPhase 3AmgenNCT05920356Written as Sotorasib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Sotorasib
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Sotorasib
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Sotorasib
- A Study of Sotorasib in People With Non-Small Cell Lung CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06582771Written as Sotorasib
- Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingPhase 1/2National Cancer Institute (NCI)NCT07012031Written as Sotorasib
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingPhase 3AmgenNCT06252649Written as Sotorasib
- A Study of Sotorasib in People With Brain TumorsRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT06807619Written as Sotorasib
- Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapyRecruitingPhase 2Fundación GECPNCT05398094Written as Sotorasib
- Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic AdenocarcinomaRecruitingPhase 1Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)NCT06892054Written as Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
- Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 1City of Hope Medical CenterNCT06249282Written as Sotorasib
- Ladarixin With Sotorasib in Advanced NSCLCRecruitingPhase 1NYU Langone HealthNCT05815173Written as Sotorasib
- Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12CRecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT05631249Written as Sotorasib 120Mg Tab
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingPhase 1/2Effector TherapeuticsNCT04092673Written as Sotorasib
- Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With ComorbiditiesRecruitingPhase 2Vestre Viken Hospital TrustNCT05311709Written as sotorasib
- An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to SotorasibNot yet recruitingPhase 2Yonsei UniversityNCT05451056Written as sotorasib
- A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT06333678Written as Sotorasib
- Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).CompletedPhase 3AmgenNCT04303780Written as AMG 510
- Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationCompletedPhase 3AmgenNCT05198934Written as Sotorasib
- A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentTerminatedPhase 2AmgenNCT04933695Written as Sotorasib
See all 50 studies that test sotorasib →
Given in every arm · 11 — sotorasib is usual care beside what is tested
- A 2-part Phase 1/2 Open-label Trial on ODM-212RecruitingPhase 1/2Orion Corporation, Orion PharmaNCT07563738Written as sotorasib
- CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerNot yet recruitingPhase 2Roswell Park Cancer InstituteNCT07543172Written as Sotorasib
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationRecruitingPhase 2AmgenNCT07172919Written as Sotorasib
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid TumorsRecruitingPhase 1Vividion Therapeutics, Inc.NCT06804824Written as Sotorasib
- Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT05638295Written as Sotorasib
- A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C MutationActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05118854Written as AMG 510
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)CompletedPhase 1/2AmgenNCT03600883Written as sotorasib
- Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active, not recruitingPhase 1AmgenNCT06333951Written as Sotorasib
- Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsTerminatedPhase 1Deciphera Pharmaceuticals, LLCNCT04892017Written as Sotorasib
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as Sotorasib
- JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid TumorsCompletedPhase 1/2Allist Pharmaceuticals, Inc.NCT04720976Written as Sotorasib
As the comparator · 1 — what is tested is compared with sotorasib
Codes
What other systems call sotorasib · ClinicalTrials.gg INT001295
- MeSH (NLM) C000706028sotorasibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2B2VM6UC8GSOTORASIBConfirmed FDA, NLM, Wikidata
- RxNorm 2550714One source FDA
- Wikidata Q75175937sotorasibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C154287SotorasibOne source FDA
- DrugBank DB15569One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706028 | sotorasib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2B2VM6UC8G | SOTORASIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2550714 | — | One source FDA |
| Wikidata | Q75175937 | sotorasib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C154287 | Sotorasib | One source FDA |
| DrugBank | DB15569 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.